JP6138950B2 - 新規化合物及び医薬における使用法 - Google Patents

新規化合物及び医薬における使用法 Download PDF

Info

Publication number
JP6138950B2
JP6138950B2 JP2015536220A JP2015536220A JP6138950B2 JP 6138950 B2 JP6138950 B2 JP 6138950B2 JP 2015536220 A JP2015536220 A JP 2015536220A JP 2015536220 A JP2015536220 A JP 2015536220A JP 6138950 B2 JP6138950 B2 JP 6138950B2
Authority
JP
Japan
Prior art keywords
group
nmr
mhz
cdcl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015536220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533154A (ja
JP2015533154A5 (enExample
Inventor
グリフィン，マーチン
ラスボーン，ダニエル
エデュアルド バダロ，レオナ
エデュアルド バダロ，レオナ
Original Assignee
アストン ユニバーシティ
アストン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アストン ユニバーシティ, アストン ユニバーシティ filed Critical アストン ユニバーシティ
Publication of JP2015533154A publication Critical patent/JP2015533154A/ja
Publication of JP2015533154A5 publication Critical patent/JP2015533154A5/ja
Application granted granted Critical
Publication of JP6138950B2 publication Critical patent/JP6138950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015536220A 2012-10-09 2013-10-09 新規化合物及び医薬における使用法 Active JP6138950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1218084.0A GB201218084D0 (en) 2012-10-09 2012-10-09 Novel compounds and methods for use in medicine
GB1218084.0 2012-10-09
PCT/GB2013/052631 WO2014057266A1 (en) 2012-10-09 2013-10-09 Acylpiperazines as inhibitors of transglutaminase and their use in medicine

Publications (3)

Publication Number Publication Date
JP2015533154A JP2015533154A (ja) 2015-11-19
JP2015533154A5 JP2015533154A5 (enExample) 2017-03-16
JP6138950B2 true JP6138950B2 (ja) 2017-05-31

Family

ID=47294510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015536220A Active JP6138950B2 (ja) 2012-10-09 2013-10-09 新規化合物及び医薬における使用法

Country Status (6)

Country Link
US (1) US9656978B2 (enExample)
EP (1) EP2906543B1 (enExample)
JP (1) JP6138950B2 (enExample)
CN (1) CN104837821B (enExample)
GB (1) GB201218084D0 (enExample)
WO (1) WO2014057266A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201218084D0 (en) 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
EP3607948A1 (en) 2018-08-07 2020-02-12 Aarhus Universitet Tissue transglutaminase modulators for medicinal use
WO2022213198A1 (en) * 2021-04-08 2022-10-13 University Of Ottawa Arylacetyl inhibitors of tg2 and uses thereof
WO2023135425A1 (en) * 2022-01-13 2023-07-20 Aston University Inhibitors of transglutaminase
GB202310246D0 (en) 2023-07-04 2023-08-16 Univ Aston New compounds
GB202310233D0 (en) 2023-07-04 2023-08-16 Univ Aston New compounds
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2628199B2 (ja) 1988-09-26 1997-07-09 富士薬品工業株式会社 新規なアシルアミノ酸およびアシルペプチド化合物
CA2022115A1 (en) * 1989-07-31 1991-02-01 David C. Remy Imidazole compounds and their use as transglutaminase inhibitors
US5721365A (en) * 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
WO1996030378A1 (en) * 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Bisphosphonic acid derivatives
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
CA2226740A1 (en) 1995-07-13 1997-01-30 Mitsuyoshi Azuma Piperazine derivative and its uses
DE69625575T2 (de) * 1995-10-25 2003-09-25 Senju Pharmaceutical Co., Ltd. Angiogense-Inhibitor
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
EP2607362B1 (en) * 2005-02-17 2014-12-31 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010075356A1 (en) * 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
WO2013022550A2 (en) 2011-08-10 2013-02-14 President And Fellows Of Harvard College Small molecule inhibitors of ebola and lassa fever viruses
GB201218084D0 (en) 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine

Also Published As

Publication number Publication date
JP2015533154A (ja) 2015-11-19
EP2906543B1 (en) 2019-01-02
GB201218084D0 (en) 2012-11-21
US20150259310A1 (en) 2015-09-17
WO2014057266A1 (en) 2014-04-17
US9656978B2 (en) 2017-05-23
EP2906543A1 (en) 2015-08-19
CN104837821A (zh) 2015-08-12
CN104837821B (zh) 2018-11-13

Similar Documents

Publication Publication Date Title
JP6138950B2 (ja) 新規化合物及び医薬における使用法
KR102508739B1 (ko) Magl 억제제의 결정형
ES2534544T3 (es) Compuestos de imidazotiazol moduladores de sirtuina
CN114341133B (zh) 具有usp30抑制剂活性的取代的氰基吡咯烷类
JP6134731B2 (ja) 抗凝固剤拮抗剤
IL229246A (en) Partially saturated tricyclic compounds and preparation and use methods
CN102464701B (zh) 一类新型化合物、其制备方法及用途
KR20160067840A (ko) 펩티드-올리고우레아 키메라 화합물 및 이의 사용 방법
RU2528333C2 (ru) Соединения и способы лечения боли и других заболеваний
KR20240108412A (ko) 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
JP2025504438A (ja) トランスグルタミナーゼの阻害剤
US8815847B2 (en) [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
ES2686675T3 (es) Agente terapéutico para enfermedad ocular
JP2008019188A (ja) 新規カルノシン誘導体及び組成物
WO2020052509A1 (zh) 作为钠通道阻滞剂的磺酰胺类化合物及其用途
JP2005512957A (ja) ポリｑ−凝集の阻害剤
ES2977619T3 (es) Compuestos para el tratamiento de la epilepsia, trastornos neurodegenerativos y otros trastornos del SNC
EP2805705B1 (en) Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
HK40077361A (en) N-cyanopyrrolidines with activity as usp30 inhibitors
NZ619685B2 (en) [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
JPWO2002048096A1 (ja) ヒドラゾン誘導体およびその医薬用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170126

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170426

R150 Certificate of patent or registration of utility model

Ref document number: 6138950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250